Shandong Missile Biologic Products

Shandong Taibang Biological Products (formerly Shandong Missile Biologic Products) is a leading Chinese biopharmaceutical company specializing in the development and manufacture of plasma-based products. As the core operating subsidiary of China Biologic Products, Inc., the company produces a wide range of essential therapies, including human albumin, intravenous immunoglobulin (IVIG), and specialized immunoglobulins for rabies and hepatitis B. It also develops coagulation factors such as Factor VIII and Factor IX for the treatment of hemophilia. Headquartered in Tai'an, Shandong, the company operates a network of plasma collection stations and maintains state-of-the-art GMP manufacturing facilities. Following a period as a Nasdaq-listed entity, the company was taken private in 2021 by a consortium of private equity investors.